5 completed, 4 recruiting, 2 terminated. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Recruiting 4, Terminated 2 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow pegcetacoplan: new trials by email Literature Review of pegcetacoplan trials Research Report on pegcetacoplan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 35 | 2026-02-16 | 2026-08-19 |
| A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | Recruiting | Apellis Pharmaceuticals, Inc. | 240 | 2025-06-23 | 2026-06-24 |
| A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy BI 771716, Pegcetacoplan, Sham comparator to BI 771716 - Macular Degeneration, Age-related, Geographic Atrophy | Phase 2 | Completed | Boehringer Ingelheim | 202 | 2025-01-06 | 2026-11-12 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation Pegcetacoplan - Transplant-Associated Thrombotic Microangiopathy | Phase 2 | Completed | Swedish Orphan Biovitrum | 12 | 2022-02-01 | 2025-11-28 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria | Phase 2 | Recruiting | Apellis Pharmaceuticals, Inc. | 12 | 2021-02-04 | 2026-06-26 |
| MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Pegcetacoplan (APL-2), Placebo - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | Terminated | Apellis Pharmaceuticals, Inc. | 249 | 2020-09-30 | 2025-04-24 |
| A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH Pegcetacoplan - PNH | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 4 | 2018-08-16 | 2020-12-22 |
| Pegcetacoplan (APL-2) in Neovascular AMD Pegcetacoplan - Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | Terminated | Apellis Pharmaceuticals, Inc. | 17 | 2018-02-14 | 2020-09-16 |
| Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy Pegcetacoplan, Sham Procedure - Geographic Atrophy | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 246 | 2015-09-24 | 2020-10-06 |
Geographic Atrophy (2) · Hemoglobinuria, Paroxysmal (2) · Amyotrophic Lateral Sclerosis (1) · Anemia (1) · Anemia, Hemolytic (1) · Fallopian Tube Neoplasms (1) · Glomerulonephritis, Membranoproliferative (1) · Hematologic Diseases (1) · Hemoglobinuria (1) · Hemolysis (1) · Macular Degeneration (1) · Motor Neuron Disease (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Apellis Pharmaceuticals, Inc. (7) · Roswell Park Cancer Institute (2) · Boehringer Ingelheim (1) · Swedish Orphan Biovitrum (1)
United States (10) · France (4) · Spain (4) · Australia (3) · Italy (3) · Netherlands (3) · United Kingdom (3) · Czechia (2) · Serbia (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Germany (1)
Federico Grossi, MD, PhD (2) · Christos Fountzilas (1) · Emese Zsiros (1) · Federico Grossi, MD PhD (1)
PMID 35113137, PMID 35860926, PMID 35869170, PMID 35948209, PMID 36284220, PMID 37314061, PMID 37715860, PMID 38752918, PMID 39522752
2023 (1), R01CA267690 (1)